APA

Flores-Pérez A., Rafaelli L. E., Ramírez-Torres N., Aréchaga-Ocampo E., Frías S., Sánchez S., Marchat L. A., Hidalgo-Miranda A., Quintanar-Jurado V., Rodríguez-Cuevas S., Bautista-Piña V., Carlos-Reyes A. & López-Camarillo C. (20150122). RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy. : Cancer biology & therapy.

Chicago

Flores-Pérez Ali, Rafaelli Lourdes E, Ramírez-Torres Nayeli, Aréchaga-Ocampo Elena, Frías Sara, Sánchez Silvia, Marchat Laurence A, Hidalgo-Miranda Alfredo, Quintanar-Jurado Valeria, Rodríguez-Cuevas Sergio, Bautista-Piña Verónica, Carlos-Reyes Angeles and López-Camarillo César. 20150122. RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy. : Cancer biology & therapy.

Harvard

Flores-Pérez A., Rafaelli L. E., Ramírez-Torres N., Aréchaga-Ocampo E., Frías S., Sánchez S., Marchat L. A., Hidalgo-Miranda A., Quintanar-Jurado V., Rodríguez-Cuevas S., Bautista-Piña V., Carlos-Reyes A. and López-Camarillo C. (20150122). RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy. : Cancer biology & therapy.

MLA

Flores-Pérez Ali, Rafaelli Lourdes E, Ramírez-Torres Nayeli, Aréchaga-Ocampo Elena, Frías Sara, Sánchez Silvia, Marchat Laurence A, Hidalgo-Miranda Alfredo, Quintanar-Jurado Valeria, Rodríguez-Cuevas Sergio, Bautista-Piña Verónica, Carlos-Reyes Angeles and López-Camarillo César. RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy. : Cancer biology & therapy. 20150122.